Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Multicellular tumor spheroids and tumoroids are considered ideal in vitro models that reflect the features of the tumor microenvironment. Biomimetic components resembling the extracellular matrix form scaffolds to provide structure to 3-dimensional (3D) culture systems, supporting the growth of both spheroids and tumoroids. Although Matrigel has long been used to support 3D culture systems, batch variations, component complexity, and the use of components derived from tumors are complicating factors. To address these issues, we developed the ACD 3D culture system to provide better control and consistency. We evaluated spheroid and tumoroid formation using the ACD 3D culture system, including the assessment of cell viability and cancer marker expression. Under ACD 3D culture conditions, spheroids derived from cancer cell lines exhibited cancer stem cell characteristics, including a sphere-forming size and the expression of stem cell marker genes. The ACD 3D culture system was also able to support patient-derived primary cells and organoid cell cultures, displaying adequate cell growth, appropriate morphology, and resistance to oxaliplatin treatment. These spheroids could also be used for drug screening purposes. In conclusion, the ACD 3D culture system represents an efficient tool for basic cancer research and therapeutic development.

Details

Title
A Novel 3D Culture Scaffold to Shorten Development Time for Multicellular Tumor Spheroids
Author
Yang, Cian-Ru 1 ; Chu-Ting, Liang 2 ; Tsai, Shih-Chieh 2 ; Yu-Chun, Wu 2 ; Ching-Wen, Liu 2 ; Hui-Hua, Yang 3 ; Ting-Yuan, Tu 4   VIAFID ORCID Logo  ; Yueh-Chun, Lee 5   VIAFID ORCID Logo  ; Kuei-Yang Hsiao 6   VIAFID ORCID Logo  ; Wei-Chun, Chang 1 ; Wen-Lung, Ma 7   VIAFID ORCID Logo 

 Ph.D. Program for Health Science and Industry, China Medical University, Taichung 404, Taiwan; Department of Medical Research, Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung 404, Taiwan 
 GEcoll Biomedical Co., Ltd., Tainan Science Park, Tainan 744, Taiwan 
 Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan; Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien 970, Taiwan 
 Department of Biomedical Engineering, National Cheng Kung University, Tainan 701, Taiwan 
 School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan 
 Institute of Biochemistry, College of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan 
 Ph.D. Program for Health Science and Industry, China Medical University, Taichung 404, Taiwan; Department of Medical Research, Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung 404, Taiwan; Department of Nursing, Asia University, Taichung 413, Taiwan 
First page
13962
Publication year
2022
Publication date
2022
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2739443035
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.